Performance of noninvasive fibrosis indices in chronic hepatitis B during pretreatment and post-treatment periods.
Biomark Med
; 17(19): 799-809, 2023 10.
Article
en En
| MEDLINE
| ID: mdl-38179991
ABSTRACT
Background:
Pretreatment and post-treatment performances of noninvasive fibrosis indices were determined in patients with chronic hepatitis B.Method:
This was a retrospective, single-center study.Results:
The best area under the receiver operating characteristic curve values were detected for aspartate aminotransferase-to-alanine aminotransferase ratio (0.685) for ≥F2, Fibrosis Index (FI; 0.703) for ≥F3; FI (0.872) for ≥F4 and FI (0.864) for cirrhosis. After antiviral treatment, the best area under the receiver operating characteristic curve values were detected in aspartate aminotransferase-to-alanine aminotransferase ratio (0.615) for ≥F2; in FI based on four factors (FIB-4; 0.634) for ≥F3; in FIB-4 (0.678) for ≥F4 and in FIB-4 (0.814) for cirrhosis.Conclusion:
FIB-4 and FI showed better performance in defining advanced fibrosis (≥F4) and cirrhosis.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Hepatitis B Crónica
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Biomark Med
/
Biomark. med. (Online)
/
Biomarkers in medicine (Online)
Asunto de la revista:
BIOQUIMICA
/
MEDICINA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Turquía
Pais de publicación:
Reino Unido